ESSA Pharma Inc. (EPIX) is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, dedicated to the discovery and development of innovative therapies for prostate cancer. Leveraging its proprietary drug platform, ESSA aims to address significant unmet medical needs in oncology, particularly for advanced prostate cancer. With a robust pipeline and strategic partnerships, the company is well-positioned to advance its lead candidates through clinical trials and seek regulatory approval, ultimately enhancing treatment options for patients.